7th Feb 2014 08:19
LONDON (Alliance News) - Oxford Pharmascience Group PLC Friday said its clinical trial application for OXP001 400 milogram reduced gastric irritation Ibuprofen has received approval from the UK Medicines and Healthcare Products Regulatory Agency and the Ethics Review Committee.
The company, which redevelops medicines to make them better, safer and easier to take, said its OXP001 product delivers 400 mg of ibuprofen via its OXPzero technology and aims to provide significantly reduced risks of gastrointestinal side effects when used in the treatment of conditions requiring the chronic use of nonsteroidal anti-inflammatory drugs.
Chronic use of nonsteroidal anti-inflammatory drugs causes well documented gastrointestinal side effects, including ulcers and bleeding that can lead to significant morbidity and mortality in many patients.
"Securing regulatory approval for our initial in-human clinical trial has achieved another important milestone in the development of safer NSAIDs via our OXPZero technology," the company's Chief Technology Officer Marcelo Bravo said in a statement.
Oxford Pharmascience shares were down 0.6% at 4.05 pence early Friday.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group